• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

    2/11/22 9:06:31 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NERV alert in real time by email
    SC 13G/A 1 d307701dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Minerva Neurosciences, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    603380106

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 603380106    13G    Page 2 of 5 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Dr. Remy Luthringer

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      France

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      1,059,761

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      1,059,761

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,059,761

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.5%

    12  

      TYPE OF REPORTING PERSON

     

      IN


    CUSIP No. 603380106    13G    Page 3 of 5 Pages

     

    Item 1(a). Name of Issuer:

    Minerva Neurosciences, Inc. (the “Issuer”)

    Item 1(b). Address of Issuer’s Principal Executive Offices:

    The Issuer’s principal executive offices are located at 1601 Trapelo Road, Suite 286, Waltham, MA 02451.

    Item 2(a). Name of Persons Filing:

    Dr. Remy Luthringer

    Item 2(b). Address of Principal Business Office or, if None, Residence:

    c/o Minerva Neurosciences, Inc.

    1601 Trapelo Road, Suite 286

    Waltham, MA 02451

    Item 2(c). Citizenship:

    France

    Item 2(d). Title of Class of Securities:

    Common Stock, $0.0001 par value per share (the “Common Stock”)

    Item 2(e). CUSIP Number:

    603380106

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

    Not applicable.


    CUSIP No. 603380106    13G    Page 4 of 5 Pages

     

    Item 4.

    Ownership.

      (a)

    1,059,761 shares of Common Stock, which consists of (a) 926,604 shares of Common Stock beneficially owned by Wint2felden Holding SA, a company wholly owned by Dr. Luthringer; (b) 66,490 shares of Common Stock owned by Dr. Luthringer himself, and (c) options to purchase 66,667 shares of common stock that are exercisable within 60 days of December 31, 2021.

      (b)

    Percent of Class: 2.5%

      (c)

    Number of shares as to which such person has:

      (i)

    sole power to vote or to direct the vote: 1,059,761

      (ii)

    shared power to vote or to direct the vote: 0

      (iii)

    sole power to dispose or to direct the disposition: 1,059,761

      (iv)

    shared power to dispose or to direct the disposition: 0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    CUSIP No. 603380106    13G    Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated February 11, 2022

     

    By:

     

    /s/ Dr. Remy Luthringer

     

    Dr. Remy Luthringer

    Get the next $NERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NERV

    DatePrice TargetRatingAnalyst
    3/4/2022$10.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NERV
    Leadership Updates

    Live Leadership Updates

    See more
    • Minerva Neurosciences Announces Promotion of Geoff Race to President

      Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President. Minerva's Senior Vice President and Chief Accounting Officer, Frederick Ahlholm, has been promoted to Chief Financial Officer. The appointments are effective immediately. These latest leadership

      10/11/21 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

      WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud's retirement and transition to an advisory role and Dr. Ramana Kuchibhatla's appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021. Dr. Kuchibhatla will report directly to Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. "I would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage cl

      9/8/21 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Minerva Neurosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Minerva Neurosciences with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      3/4/22 6:14:09 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kupfer David

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:13 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Laghrissi-Thode Fouzia

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:16 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van Heek G Jan

      4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

      12/6/24 5:45:18 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Minerva Neurosciences Inc

      10-Q - Minerva Neurosciences, Inc. (0001598646) (Filer)

      5/13/25 7:00:34 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Minerva Neurosciences Inc

      10-K/A - Minerva Neurosciences, Inc. (0001598646) (Filer)

      4/28/25 6:46:17 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Minerva Neurosciences Inc

      10-K/A - Minerva Neurosciences, Inc. (0001598646) (Filer)

      4/21/25 4:55:27 PM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Financials

    Live finance-specific insights

    See more
    • Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

      BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. "The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of

      5/15/23 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

      BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may be accessed here and on the Company's website under Events and Presentations. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days. About Miner

      5/8/23 8:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

      BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update "In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperid

      3/8/23 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

      BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025.    Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue to be listed on the Nasdaq Capital Market. Interactions with the FDA continue with the goal of addressing questions raised in the Complete Response Letter (CRL) to our New Drug Application

      5/13/25 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

      BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.    Corporate Update As previously disclosed in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company continues to have interactions with the FDA with the goal of addressing

      2/25/25 7:00:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

      BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.    Roluperidone NDA Update As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing questions rais

      11/5/24 7:30:00 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Minerva Neurosciences Inc

      SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

      11/12/24 10:32:12 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Minerva Neurosciences Inc

      SC 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

      2/9/24 9:28:31 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

      SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

      1/18/24 10:21:16 AM ET
      $NERV
      Biotechnology: Pharmaceutical Preparations
      Health Care